Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma - PubMed (original) (raw)
. 2005 Feb;26(2):293-301.
doi: 10.1093/carcin/bgh333. Epub 2004 Nov 11.
Affiliations
- PMID: 15539404
- DOI: 10.1093/carcin/bgh333
Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma
Babett Bartling et al. Carcinogenesis. 2005 Feb.
Abstract
The receptor for advanced glycation end-products (RAGE) is a transmembrane receptor of the immunoglobulin superfamily. Several ligands binding to RAGE have been identified, including amphoterin. Experimental studies have given rise to the discussion that RAGE and its interaction with amphoterin contribute to tumour growth and metastasis. However, none of the studies considered a differential transcription profile in cancer that might change the interpretation of the study results when comparing RAGE in tumours with histologically normal tissues. Here we show that RAGE is strongly reduced at the mRNA and even more so at the protein level in non-small cell lung carcinomas compared with normal lung tissues. Down-regulation of RAGE correlates with higher tumour (TNM) stages but does not depend on the histological subtypes, squamous cell lung carcinoma and adenocarcinoma. Subsequent overexpression of full-length human RAGE in lung cancer cells (NCI-H358) showed diminished tumour growth under some conditions. While proliferation of RAGE-expressing cells was less than that of cells expressing the cytoplasmic domain deletion mutant DeltacytoRAGE or mock-transfected NCI-H358 in monolayer cultures, RAGE cells also formed smaller tumours in spheroid cultures and in vivo in athymic mice compared with DeltacytoRAGE cells. Moreover, we observed a more epithelial growth of RAGE-expressing, but also of DeltacytoRAGE-expressing, cells on collagen layers, whereas mock NCI-H358 cells kept their tumour morphology. This observation was supported by immunofluorescence analyses demonstrating that RAGE preferentially localizes at intercellular contact sites, independent of expression of the cytoplasmic domain. Thus, down-regulation of RAGE may be considered as a critical step in tissue reorganization and the formation of lung tumours.
Similar articles
- Proliferative stimulus of lung fibroblasts on lung cancer cells is impaired by the receptor for advanced glycation end-products.
Bartling B, Demling N, Silber RE, Simm A. Bartling B, et al. Am J Respir Cell Mol Biol. 2006 Jan;34(1):83-91. doi: 10.1165/rcmb.2005-0194OC. Epub 2005 Sep 15. Am J Respir Cell Mol Biol. 2006. PMID: 16166741 - Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer.
Kuniyasu H, Oue N, Wakikawa A, Shigeishi H, Matsutani N, Kuraoka K, Ito R, Yokozaki H, Yasui W. Kuniyasu H, et al. J Pathol. 2002 Feb;196(2):163-70. doi: 10.1002/path.1031. J Pathol. 2002. PMID: 11793367 - Receptor for advanced glycation end products and its ligands: a journey from the complications of diabetes to its pathogenesis.
Kim W, Hudson BI, Moser B, Guo J, Rong LL, Lu Y, Qu W, Lalla E, Lerner S, Chen Y, Yan SS, D'Agati V, Naka Y, Ramasamy R, Herold K, Yan SF, Schmidt AM. Kim W, et al. Ann N Y Acad Sci. 2005 Jun;1043:553-61. doi: 10.1196/annals.1338.063. Ann N Y Acad Sci. 2005. PMID: 16037278 Review. - Glycosaminoglycans are functional ligands for receptor for advanced glycation end-products in tumors.
Mizumoto S, Sugahara K. Mizumoto S, et al. FEBS J. 2013 May;280(10):2462-70. doi: 10.1111/febs.12156. Epub 2013 Feb 24. FEBS J. 2013. PMID: 23360476 Review.
Cited by
- Diagnostic Utility and Tendency of Bronchial and Serum Soluble Receptor for Advanced Glycation EndProducts (sRAGE) in Lung Cancer.
Kim T, Kim SJ, Choi H, Shin TR, Sim YS. Kim T, et al. Cancers (Basel). 2023 May 18;15(10):2819. doi: 10.3390/cancers15102819. Cancers (Basel). 2023. PMID: 37345156 Free PMC article. - Effects of AGEs, sRAGE and HMGB1 on Clinical Outcomes in Multiple Myeloma.
Geduk A, Oztas B, Eryılmaz BH, Demirsoy ET, Menguc MU, Unal S, Mersin S, Polat MG, Aygun K, Yenihayat EM, Albayrak H, Erol HA, Balcı S, Mehtap O, Tarkun P, Hacihanefioglu A. Geduk A, et al. Indian J Hematol Blood Transfus. 2023 Apr;39(2):220-227. doi: 10.1007/s12288-022-01574-6. Epub 2022 Oct 17. Indian J Hematol Blood Transfus. 2023. PMID: 37006982 Free PMC article. - Insulin/IGF Axis and the Receptor for Advanced Glycation End Products: Role in Meta-inflammation and Potential in Cancer Therapy.
Vella V, Lappano R, Bonavita E, Maggiolini M, Clarke RB, Belfiore A, De Francesco EM. Vella V, et al. Endocr Rev. 2023 Jul 11;44(4):693-723. doi: 10.1210/endrev/bnad005. Endocr Rev. 2023. PMID: 36869790 Free PMC article. Review. - The Receptor for Advanced Glycation Endproducts (RAGE) and Its Ligands S100A8/A9 and High Mobility Group Box Protein 1 (HMGB1) Are Key Regulators of Myeloid-Derived Suppressor Cells.
Ostrand-Rosenberg S, Huecksteadt T, Sanders K. Ostrand-Rosenberg S, et al. Cancers (Basel). 2023 Feb 6;15(4):1026. doi: 10.3390/cancers15041026. Cancers (Basel). 2023. PMID: 36831371 Free PMC article. Review. - RAGE Inhibitors for Targeted Therapy of Cancer: A Comprehensive Review.
Faruqui T, Khan MS, Akhter Y, Khan S, Rafi Z, Saeed M, Han I, Choi EH, Yadav DK. Faruqui T, et al. Int J Mol Sci. 2022 Dec 23;24(1):266. doi: 10.3390/ijms24010266. Int J Mol Sci. 2022. PMID: 36613714 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical